Skip to content
Screener

Perspective Therapeutics CATX Q4 2025 Annual earnings

Reported March 16, 2026 · Before market open

Revenue$43.0KMiss by $189.5K
EPS-$0.51Miss by $0.14
Revenue estimate$232.5K
EPS estimate-$0.37

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$62.1K
EPS estimate-$0.24

Financials

Q4 2025

Income statement

See full
Operating income-$39.8M+11.5%
Net income-$37.5M+6.7%
EPS (diluted)-$0.51+16.4%

Balance sheet

See full
Cash & equivalents$30.6M-50.3%
Total debt$3.2M-20.3%
Total equity$207.0M-28.8%
Total assets$267.0M-21.7%

Cash flow

See full
Operating cash flow-$24.7M+7.3%
CapEx$5.1M-65.3%
Free cash flow-$29.7M+27.9%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$204.43M-5.2%
Enterprise value$177M+12.0%

Returns & leverage

See full
Return on equity-41.4%-1.7pp
Debt / equity0×0.0×
Current ratio5.2×-7.5×

FAQ

When did Perspective Therapeutics report Q4 2025 earnings?
Perspective Therapeutics (CATX) reported Q4 2025 earnings on March 16, 2026 before market open.
What were Perspective Therapeutics's Q4 2025 revenue and EPS?
Perspective Therapeutics reported revenue of $43.0K and eps of $-0.51 for Q4 2025.
Did Perspective Therapeutics beat estimates in Q4 2025?
Revenue missed the consensus estimate of $232.5K by $189.5K. EPS missed the consensus estimate of $-0.37 by $0.14.
How did Perspective Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 81.6% from $234.0K a year earlier and eps declined 104.0% from $-0.25.
Where can I find Perspective Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0000728387-26-000003) and the 10-K periodic report (0000728387-26-000004) directly on SEC EDGAR. The filing index links above go to sec.gov.